Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aralast NP in New-onset Type 1 Diabetes
NCT01183455Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2010
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha1-proteinase inhibitor in type 1 diabetes mellitus (T1D), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Oct 2010; status: withdrawn.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01183455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183455.